Penumbra, Earnings Call and Q4
Hosted on MSN1mon
Penumbra spikes after Stryker- Inari dealPenumbra (PEN) is “likely to carry the most ... thrombectomy technology for peripheral vascular diseases like DVT and PE,” Jennings, with a Buy recommendation on Stryker (SYK), added.
Penumbra, Inc.’s PEN thrombectomy business is thriving, driven by growing sales of the U.S. vascular thrombectomy and CAVT (computer-assisted vacuum thrombectomy) line of products. The company ...
Penumbra closed 2024 on a strong note, driven by robust growth in its U.S. thrombectomy business and the successful introduction of new CAVT products. Despite challenges in the China market and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback